Document Detail

Cardiac disease in beta-thalassaemia major: Is it reversible?
MedLine Citation:
PMID:  16865210     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: The aim of this study was to evaluate the spectrum of cardiac involvement and its outcome in beta-thalassaemia major. METHODS: There were 75 patients with a mean age of 13.8 (+/- 5.5) years, of whom 33 were male and 42 were female. Clinical history, examination and laboratory investigations were assessed. Electrocardiograms, chest radiographs and echocardiograms were reviewed. RESULTS: 44 patients had cardiac involvement in the form of left ventricular systolic dysfunction in 17, diastolic dysfunction in 22, pericardial effusion in 12 and pulmonary hypertension in 12 patients. With intense chelation therapy and cardiac medications, the condition of 13 of 17 patients with systolic dysfunction, and four of 22 with diastolic dysfunction, improved. CONCLUSION: Cardiac disease is a common complication of siderotic disease in thalassaemia major and it can be prevented with regular chelation. This study has shown improved systolic function after regular chelation therapy.
M Atiq; M Bana; U S Ahmed; S Bano; M Yousuf; Z Fadoo; M Khurshid
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Singapore medical journal     Volume:  47     ISSN:  0037-5675     ISO Abbreviation:  Singapore Med J     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-07-25     Completed Date:  2006-10-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0404516     Medline TA:  Singapore Med J     Country:  Singapore    
Other Details:
Languages:  eng     Pagination:  693-6     Citation Subset:  IM    
Department of Paediatrics, The Aga Khan University Hospital, PO Box 3500, Stadium Road, Karachi, Pakistan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Transfusion
Cardiotonic Agents / therapeutic use
Cardiovascular Diseases / drug therapy,  etiology*
Chelation Therapy*
Child, Preschool
Deferoxamine / therapeutic use
Ferritins / blood,  deficiency
Retrospective Studies
Risk Assessment
Risk Factors
Siderophores / therapeutic use
beta-Thalassemia / complications*,  therapy
Reg. No./Substance:
0/Cardiotonic Agents; 0/Siderophores; 70-51-9/Deferoxamine; 9007-73-2/Ferritins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prognostic factors of differentiated thyroid cancer patients in Hospital Universiti Sains Malaysia.
Next Document:  Comparison by electron microscopy of intracellular events and survival of Burkholderia pseudomallei ...